Gentian Diagnostics ASA (OSL:GENT)

Market Cap	582.79M -33.7%
Revenue (ttm)	175.92M +11.3%
Net Income	-14.79M
EPS	-0.96
Shares Out	15.46M
PE Ratio	n/a
Forward PE	17.21
Dividend	0.60 (1.58%)
Ex-Dividend Date	May 6, 2026

Volume	7,377
Open	39.70
Previous Close	37.90
Day's Range	37.50 - 39.70
52-Week Range	34.20 - 65.80
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	May 6, 2026

About Gentian Diagnostics ASA

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidne...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2001
• Employees: 64
• Stock Exchange: Oslo Børs
• Ticker Symbol: GENT

Financial Performance

In 2025, Gentian Diagnostics ASA's revenue was 176.50 million, an increase of 16.07% compared to the previous year's 152.07 million. Earnings were 13.26 million, a decrease of -70.73%.